Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Realizes Product Innovation Through Robust R&D Activities And Strategic Collaborations

LONDON, Jan. 27, 2021 (GLOBE NEWSWIRE) -- New year, new updates! Our reports have been revised for market size, forecasts, and strategies to take on 2021 after the COVID-19 impact: https://www.thebusinessresearchcompany.com/global-market-reports

According to The Business Research Company’s research report on the VEGF inhibitor market, the vascular endothelial growth factor (VEGF) inhibitor market is witnessing robust research and development activities. These research and development activities have led to increasing success rates in clinical trials. R&D is being carried out extensively by market leaders in the VEGF inhibitor market as they continuously strive to make breakthroughs in the market in the form of new and effective drugs. For instance, in April 2020, Germany based pharmaceutics company, Bayer AG received approval from the European Medicines Agency (EMA) for its new Eylea (aflibercept) injection pre-filled syringe which will provide ophthalmologists with a more efficient and convenient way to administer EYLEA across all approved indications. The pre-filled syringe requires fewer steps to prepare compared to the intravitreal injection procedure of the existing vial.

This improvement through research and development is additionally brough about with collaboration. Companies in the vascular endothelial growth factor (VEGF) inhibitor market are increasing their product innovation through strategic collaborations. To sustain their position in an increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated with each other, as well as with academic and research institutions in this market by way of partnerships, in or out of licensing deals, this trend has been increasing in recent years.

For instance, in April 2018, Switzerland based biopharmaceutical company, Molecular Partners collaborated with UK based pharmaceutical AstraZeneca, for the trial of its oncology candidate MP0250 with AstraZeneca’s antineoplastic agent osimertinib (Tagrisso) in Phase Ib/II studies. MP0250 prevents tumor growth by inhibiting two growth factors, hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF).ⁱ In June 2020, Roche launched Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy.

The global vascular endothelial growth factor inhibitor market size reached a value of nearly $30.31 billion in 2020, having increased at a compound annual growth rate (CAGR) of 7.8% since 2015. The market is expected to grow from $30.31 billion in 2020 to $46.63 billion in 2025 at a rate of 9.0%. The VEGF market is then expected to grow at a CAGR of 6.3% from 2025 and reach $63.37 billion in 2030.

The Business Research Company’s report titled Vascular Endothelial Growth Factor (VEGF) Inhibitor Global Market Report 2020-30: COVID-19 Impact and Recovery covers major VEGF inhibitor companies, VEGF inhibitor market share by company, VEGF inhibitor manufacturers, VEGF inhibitor infrastructure market size, and VEGF inhibitor market forecasts. The report also covers the global VEGF inhibitor market and its segments.

Request For A Sample Of The Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3437&type=smp

The vascular endothelial growth factor inhibitor industry is supported by the increased prevalence of cancer, increased number of government initiatives in both developed and developing countries and an increase in geriatric population leading to rise in the number of ophthalmic cases such as AMD, diabetic retinopathy, and others. The strong ophthalmic drug pipelines of different top pharmaceutical companies will drive the global market growth. North America and Europe are well-established and mature markets where most of the larger pharmaceutical and biopharmaceutical companies are located. Developing regions such as Asia-Pacific, the Middle East and Africa, are fast-growing markets. Vascular endothelial growth factor (VEGF) inhibitor manufacturers should consider investing extensively in R&D activities for the development of effective and innovative drugs, and alongside should carry out strategic collaborations to boost innovations and establish category leadership.

Vascular Endothelial Growth Factor (VEGF) Inhibitor Global Market Report 2020-30: COVID-19 Impact and Recovery is one of a series of new reports from The Business Research Company that provide market overviews, analyze and forecast market size and growth for the whole market, segments and geographies, trends, drivers, restraints, leading competitors’ revenues, profiles and market shares in over 1,000 industry reports, covering over 2,500 market segments and 60 geographies. The report also gives in-depth analysis of the impact of COVID-19 on the market. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. A highly experienced and expert team of analysts and modelers provides market analysis and forecasts. The reports identify top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.

Here Is A List Of Similar Reports By The Business Research Company:

Oncology Drugs Market - By Type (Blood Cancer, Breast Cancer, Lung Cancer, Prostate cancer, Colorectal Cancer, Cervical cancer, Kidney cancer, Gastric Cancer, Brain Tumor, Skin Cancer, Ovarian Cancer, Bladder Cancer, Pancreatic Cancer, Thyroid cancer, Others), By Drug Class Type (Targeted Therapy, Immunotherapy (Biologic Therapy), Chemotherapy, Hormonal Therapy), By Distribution Channel (Retail Pharmacies/Drug Stores, Hospital Pharmacies, Others), By Route Of Administration (Oral, Parenteral, Others), By Drug Classification (Branded, Generic), And By Region, Opportunities And Strategies - Global Forecast To 2030

Ophthalmology Drugs Market - By Type (Antiglaucoma Drugs, Dry Eye Medication And Other Ophthalmological Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores And Others), By Drug Classification (Branded Drugs And Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs) And, By Region, Opportunities And Strategies – Global Forecast To 2030

Dry Eye Medication Market - By Type (Aqueous Dry Eye Syndrome, Evaporative Dry Eye Syndrome), By End-User (Hospital Pharmacies, Eye Health Clinics, Retail Pharmacies, Online Pharmacies), By Product Type (Liquid Drops, Gel, Liquid Wipes, Eye Ointment), And By Region, Opportunities And Strategies – Global Forecast To 2030

CAR-T Therapy Market - By Target Antigen (CD19 Therapy, CD22 Therapy, BCMA Therapy, Others), By Application (Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma, Others), And By Region, Opportunities And Strategies - Global Forecast To 2030

Interested to know more about The Business Research Company?

The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.

The World’s Most Comprehensive Database

The Business Research Company’s flagship product, Global Market Model, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps.

ⁱ https://www.pharmaceutical-technology.com/comment/astrazeneca-deal-shows-promise-molecular-partners-lung-cancer-therapy/